Focused On-demand Library for Protein-tyrosine sulfotransferase 2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
O60704

UPID:
TPST2_HUMAN

ALTERNATIVE NAMES:
Tyrosylprotein sulfotransferase 2

ALTERNATIVE UPACC:
O60704; B3KQA7; Q6FI98; Q9H0V4

BACKGROUND:
The enzyme Protein-tyrosine sulfotransferase 2, also referred to as Tyrosylprotein sulfotransferase 2, is pivotal in the biochemical landscape, facilitating the O-sulfation of tyrosine residues. This action is essential for the modification of polypeptides, utilizing 3'-phosphoadenylyl sulfate (PAPS) as a cosubstrate, thereby influencing various biological processes and signaling mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Protein-tyrosine sulfotransferase 2 unveils potential avenues for therapeutic intervention. Its key role in post-translational modifications positions it as a valuable target for developing treatments against disorders linked to protein synthesis and modification anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.